Agilus Diagnostics Limited is coming up with an IPO. The offer consists of an offer for the sale of 1.42 crore existing equity shares worth INR 1.42 crores. The company has mainly developed an IPO to provide listing benefits to the existing shareholders and gain the benefits of listing.
Agilus Diagnostics Ltd IPO – Important Details
| Agilus Diagnostics Limited IPO Date | NA |
| Agilus Diagnostics Limited IPO Listing Date | NA |
| Agilus Diagnostics Limited IPO Price | NA |
| Agilus Diagnostics Limited IPO Lot Size | NA |
| Agilus Diagnostics Limited IPO Total Issue Size | Approx INR 1.42 crores |
| Agilus Diagnostics Limited IPO Basis of Allotment | NA |
| Agilus Diagnostics Limited IPO Initiation of Refunds | NA |
| Agilus Diagnostics Limited IPO Credit of Shares to Demat | NA |
| Agilus Diagnostics Limited IPO Issue Type | Book Built Issue IPO |
| Agilus Diagnostics Limited IPO Listing At | BSE, NSE |
Agilus Diagnostics IPO – Company Profile
As of March 31, 2023, Agilus Diagnostics is India’s largest diagnostics service provider by laboratory count and second by revenue. With 413 labs, including 43 NABL-accredited, it offers diverse diagnostic services globally. In fiscal 2023, it conducted 39.07 million tests and served 16.62 million patients.
Catering to B2C and B2B segments, their diagnostics services reach individual patients through labs, home services, and digital platforms while serving healthcare providers and clinical trials. Fiscal 2023 showcased a balanced revenue split, with 54.31% from B2C and 45.69% from B2B.
Benefiting from Fortis Healthcare Limited’s expertise, they are led by MD & CEO Anand Kuppuswamy and supported by a diverse board and skilled teams. As of March 31, 2023, with 4,614 medical and scientific staff, their critical financial and operational metrics reflect strong performance and growth.
Agilus Diagnostics Ltd IPO – Fundamental Analysis
Agilus Diagnostics Limited demonstrates remarkable revenue and profit growth up to 2022, with high RoNW and EPS. However, the significant drop in revenue and profitability in 2023 raises concerns and requires a thorough analysis.
Revenue Growth:
The company’s revenue increased from ₹10,350.73 million in 2021 to ₹16,049.11 million in 2022 but decreased to ₹13,474.62 million in 2023. The decrease in 2023 requires further investigation.
Equity Fluctuation:
Equity has shown fluctuations, starting at ₹24,187.44 million in 2021 and decreasing to ₹18,661.54 million in 2022 before rising to ₹19,455.77 million in 2023.
Expenses:
While expenses have generally increased, they decreased in 2023, contributing to higher profitability.
Profit After Tax:
There is substantial profit growth from ₹1,312.45 million in 2021 to ₹5,547.08 million in 2022, but it dropped to ₹1,166.36 million in 2023, signaling potential concerns.
Return on Net Worth (RoNW):
RoNW surged from 8.95% in 2021 to an impressive 38.34% in 2022, but it decreased significantly to 6.61% in 2023.
Earnings Per Share (EPS):
EPS exhibited substantial growth, peaking at ₹70.21 in 2022 but dropping to ₹14.76 in 2023.
Net Asset Value (NAV) per Equity Share:
NAV per share increased over the years, indicating growing intrinsic value.
Total Assets and Liabilities:
Total assets have shown significant growth, while liabilities have also increased, suggesting a balanced financial structure.
Agilus Diagnostics Limited IPO Financial Information
| Particular | As of 31 March 2021 | As of 31 March 2022 | As of 31 March 2023 |
| Revenue(₹in millions) | 10,350.73 | 16,049.11 | 13,474.62 |
| Equity(₹ in millions) | 24,187.44 | 18,661.54 | 19,455.77 |
| Expenses (₹in millions) | 9,239.18 | 12,890.39 | 12,129.07 |
| Profit and Loss After Tax (₹ in millions) | 1,312.45 | 5,547.08 | 1,166.36 |
| RoNW (%) | 8.95 | 38.34 | 6.61 |
| Diluted EPS only (₹) | 16.62 | 70.21 | 14.76 |
| NAV per Equity Share (₹) | 149.13 | 219.87 | 230 |
| Total Assets (in millions) | 15,863.12 | 15,863.12 | 24,187.44 |
| Total Liabilities (in millions) | 2,749.30 | 4,138.09 | 4,731.67 |
Agilus Diagnostics Ltd IPO Peer Comparison
Agilus Diagnostics Limited’s IPO peer comparison shows it has lower revenue (₹13,474.62M) and RoNW (6.64%) compared to Dr Lal Path Labs, Metropolis, and Vijaya Diagnostic. EPS and NAV are also comparatively lower. Investors should consider peers’ stronger financials when evaluating this IPO.
| Company | Revenue (₹ in million) | Face Value per Equity Share (₹) | P/E | EPS (Basic) (₹) | EPS (Diluted) (₹) | RoNW (%) | NAV per Equity Share (Basic) (₹) |
| Agilus Diagnostics Limited | 13,474.62 | 10 | NA | 14.87 | 14.76 | 6.64 | 230 |
| Dr Lal Path Labs | 20,169.00 | 10 | 83.19 | 28.82 | 28.74 | 14.90 | 95.14 |
| Metropolis | 11,527.33 | 2 | 51.09 | 27.91 | 27.81 | 15.26 | 31.47 |
| Thyrocare | 5,270.60 | 10 | 46.85 | 12.16 | 12.14 | 12.12 | 82.02 |
| Vijaya Diagnostic | 4,592.29 | 1 | 56.37 | 8.29 | 8.26 | 16.77 | 52.75 |
Agilus Diagnostics IPO Objective
Agilus Diagnostics Limited’s objective is to make an offer to sell 1.42 crore equity shares and list these shares on stock exchanges for increased visibility and brand enhancement in the financial markets.
Agilus Diagnostics Ltd IPO Risks and Challenges
Agilus Diagnostics faces legal challenges in the brand transition case, creating uncertainties impacting operations. Ongoing regulatory notices and debt-related constraints pose risks, while operational disruptions and reliance on outsourcing affect efficiency and financial standing.
- Agilus Diagnostics underwent a brand transition from “Former Brand” to “Agilus Diagnostics,” facing legal challenges in the Delhi High Court. Shivinder Mohan Singh sought directions, and Daiichi filed a contempt petition. Pending proceedings pose risks, consume resources, and impact business, reputation, and financial conditions.
- The legal proceedings, including the brand transition case, pose uncertainties and may result in adverse orders affecting the company’s business, operations, financial condition, and cash flows. Additionally, ongoing regulatory notices and the pending Open Offers add to the uncertainty, impacting corporate actions and business operations.
- Operational interruptions, external and internal, pose risks to the diagnostic laboratory network. Events like the COVID-19 lockdown impact operations, customer retention, and costs. Increased reliance on outsourcing may affect efficiency and financial condition.
- Their ability to meet debt obligations depends on generating sufficient cash flows. Indebtedness constraints may limit flexibility, reducing funds for operations, acquisitions, and investments. Breaching covenants or failing to obtain consent can significantly affect business and operations.
Agilus Diagnostics IPO – Industry & Market Potential
The onset of the COVID-19 pandemic exposed weaknesses in India’s healthcare system. The government addressed these by expanding health insurance, establishing the PM CARES Fund, promoting telemedicine, expediting regulatory approvals, and increasing awareness to enhance pandemic management.
The diagnostics industry is transforming digitally, adopting online platforms for appointments and results. Intensified competition drives innovation, including home services and point-of-contact testing. Labs use electronic health records for efficient data management.
The healthcare industry focuses on preventive care, driving R&D in diagnostics, especially in genomics, point-of-care testing, and molecular diagnostics. International collaborations in cancer research and AI/ML integration enhance diagnostic capabilities for improved patient outcomes.
Agilus Diagnostics IPO – Type of Offer
Agilus Diagnostics is coming up with an offer to sell 1.42 crore existing shares. The following are the details of the existing shareholders who are also the promoters selling the shares:
| Name of the promoter selling shareholder | Maximum number of offered shares for sale |
| International Finance Corporation | 2,985,075 |
| NYLIM Jacob Ballas India Fund III LLC | 7,462,700 |
| Resurgence PE Investments Limited | 3,786,189 |
Agilus Diagnostics IPO Offer Size
Agilus Diagnostics Limited is launching an initial public offering (IPO). This offer involves the sale of 1.42 crore existing equity shares valued at INR 1.42 crores. The primary purpose of this IPO is to offer listing advantages to current shareholders and to leverage the benefits of being publicly listed.
Agilus Diagnostics Ltd IPO Allotment Structure
Agilus Diagnostics Limited’s IPO allocation designates 50% to Qualified Institutional Buyers (banks, mutual funds, insurance), 15% to Non-Institutional Investors (corporates, high-value individuals), and 35% to Retail Individual Investors (individuals with smaller investments), which complies with SEBI regulations.
- Qualified Institutional Buyers (QIB): As per SEBI regulations, 50% of the shares offered through the IPO will be reserved for Qualified Institutional Buyers. These include entities such as banks, mutual funds, and insurance companies.
- Non-Institutional Investors (NII): 15% of the shares will be reserved for Non-Institutional Investors. These typically include corporate bodies or individuals investing more than Rs.2 lakhs.
- Retail Individual Investors (RII): The remaining 35% of the shares will be allotted to Retail Individual Investors. These individual investors apply for shares with a total value of less than Rs.2 lakhs.
How to apply for an Agilus Diagnostics IPO?
To apply for the Agilus Diagnostics Limited IPO through Alice Blue, you would typically follow these steps:
- Open a Demat and Trading Account: If you don’t have one already, you must open a Demat and trading account with Alice Blue.
- Check for IPO Details: Once your account is active, you can check for the Agilus Diagnostics Limited IPO details in the IPO section of the Alice Blue platform.
- Place the Bid: Enter the number of shares you wish to buy and place your bid within the IPO’s price band.
- Submit the Application: Confirm all your details and submit your application.
You can apply for Agilus Diagnostics Limited’s IPO at Alice Blue in just a few clicks!
Check Allotment Status: After the allotment process, you can check the allotment status to see if you have received any shares.
Please note that the allotment of shares is not guaranteed and will depend on the demand for the IPO.
How to Check Agilus Diagnostics Limited IPO Allotment Status on Alice Blue?
Checking the allotment status of an IPO in Alice Blue is usually straightforward. Please follow these general steps:
- Log in to your Alice Blue Account: You can do this through the Alice Blue website or the trading app.
- Navigate to the Portfolio or IPO Section: This might differ based on the layout of Alice Blue’s platform, but generally, you can find the status of your IPO application under the ‘Portfolio’ or ‘IPO’ section.
- Find the IPO Allotment Status: Look for a sub-section called ‘IPO Allotment Status’ or something similar. This is where you can see the status of the IPOs you have applied for.
- Select the Agilus Diagnostics Limited IPO: If you have applied for multiple IPOs, there might be a dropdown menu or lists where you can select the IPO you are interested in. Select the Agilus Diagnostics Limited IPO.
- Check the Status: The status of your application should be displayed here. If the shares have been allocated to you, it would be mentioned here.
If you face any issues, it’s recommended to contact Alice Blue’s customer support for detailed assistance.
Apart from Alice Blue, there are other ways to check the allotment status of the Agilus Diagnostics Limited IPO:
Registrar’s Website: Visit the website of KFin Technologies Limited, the registrar of the Limited IPO. On the homepage, look for the ‘IPO Allotment Status’ option. You must enter your PAN and application number or Demat account number to check your allotment status. Click on the ‘Submit’ button to view your IPO allotment status.
NSE and BSE: You can also check the allotment status on the official websites of the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). You would need your application number and PAN to check the status.
Please note that the allotment status will only be available after the allotment process has been completed, a few days after the IPO window closes.
Agilus Diagnostics IPO Offer Registrar
The registrar for the Agilus Diagnostics Limited IPO is KFin Technologies Limited. They are responsible for ensuring the IPO allotment and refund processes are carried out smoothly.
Contact information for the registrar:
KFin Technologies Limited
Selenium Tower B, Plot No. 31-32, Gachibowli
Financial District, Nanakramguda, Serilingampally
Hyderabad -500 032, Telangana, India
Telephone: +91 40 6716 2222/ 18003094001
Email: [email protected]
Website: www.kfintech.com
Agilus Diagnostics Limited IPO FAQs
What is the allotment date of the Agilus Diagnostics Limited IPO?
The allotment date of the Agilus Diagnostics Limited IPO has not yet been announced.
What is the price band of the Agilus Diagnostics Limited IPO?
The price band of the Agilus Diagnostics Limited IPO has not yet been announced.
What is the size of the Agilus Diagnostics Limited IPO?
Agilus Diagnostics Limited is launching an IPO. This offering comprises an offer to sell 1.42 crore worth INR 1.42 crores to provide listing benefits to the existing shareholders and gain the benefits of listing.
What is the listing date of the Agilus Diagnostics Limited IPO?
The listing date of the Agilus Diagnostics Limited IPO has not yet been announced.
